These revised guidelines emphasize robust evidence supporting the notion that genes other than BRCA1/2, such as CDH1, PALB2, PTEN, and TP53, substantially elevate the risk of developing breast and/or ovarian cancer [98,99]. The gene discussed is PTEN; the disease is ovarian carcinoma.